Treatment of chronic lymphocytic leukemia and related disorders

Gautam Borthakur; Susan O'Brien

doi:10.1007/978-1-4614-3764-2_9

Treatment of chronic lymphocytic leukemia and related disorders

Gautam Borthakur, Susan O'Brien

Leukemia

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

According to SEER data, between 2003 and 2007, the median age at diagnosis for chronic lymphocytic leukemia was 72 years and age-adjusted incidence rate was 4.2 per 100,000 men and women per year. A European study estimated the 1- and 5-year prevalence rate of CLL in European Union countries to be 0.2/10,000 and 0.9/10,000, respectively [1].

Original language	English (US)
Title of host publication	Neoplastic Diseases of the Blood
Publisher	Springer New York
Pages	103-119
Number of pages	17
ISBN (Electronic)	9781461437642
ISBN (Print)	1461437636, 9781461437635
DOIs	https://doi.org/10.1007/978-1-4614-3764-2_9
State	Published - Nov 1 2013

Keywords

Alemtuzumab
CD20 antibody
Chemoimmunotherapy
Chronic lymphocytic leukemia
Cladribine
FAB
IGVH
Pentostatin
Prognostic factors
Rai
Rituximab
TP53
Treatment
ZAP-70

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-4614-3764-2_9

Cite this

@inbook{35258367e8174660a69d36cc086dde8a,

title = "Treatment of chronic lymphocytic leukemia and related disorders",

abstract = "According to SEER data, between 2003 and 2007, the median age at diagnosis for chronic lymphocytic leukemia was 72 years and age-adjusted incidence rate was 4.2 per 100,000 men and women per year. A European study estimated the 1- and 5-year prevalence rate of CLL in European Union countries to be 0.2/10,000 and 0.9/10,000, respectively [1].",

keywords = "Alemtuzumab, CD20 antibody, Chemoimmunotherapy, Chronic lymphocytic leukemia, Cladribine, FAB, IGVH, Pentostatin, Prognostic factors, Rai, Rituximab, TP53, Treatment, ZAP-70",

author = "Gautam Borthakur and Susan O'Brien",

year = "2013",

month = nov,

day = "1",

doi = "10.1007/978-1-4614-3764-2_9",

language = "English (US)",

isbn = "1461437636",

pages = "103--119",

booktitle = "Neoplastic Diseases of the Blood",

publisher = "Springer New York",

}

TY - CHAP

T1 - Treatment of chronic lymphocytic leukemia and related disorders

AU - Borthakur, Gautam

AU - O'Brien, Susan

PY - 2013/11/1

Y1 - 2013/11/1

N2 - According to SEER data, between 2003 and 2007, the median age at diagnosis for chronic lymphocytic leukemia was 72 years and age-adjusted incidence rate was 4.2 per 100,000 men and women per year. A European study estimated the 1- and 5-year prevalence rate of CLL in European Union countries to be 0.2/10,000 and 0.9/10,000, respectively [1].

AB - According to SEER data, between 2003 and 2007, the median age at diagnosis for chronic lymphocytic leukemia was 72 years and age-adjusted incidence rate was 4.2 per 100,000 men and women per year. A European study estimated the 1- and 5-year prevalence rate of CLL in European Union countries to be 0.2/10,000 and 0.9/10,000, respectively [1].

KW - Alemtuzumab

KW - CD20 antibody

KW - Chemoimmunotherapy

KW - Chronic lymphocytic leukemia

KW - Cladribine

KW - FAB

KW - IGVH

KW - Pentostatin

KW - Prognostic factors

KW - Rai

KW - Rituximab

KW - TP53

KW - Treatment

KW - ZAP-70

UR - http://www.scopus.com/inward/record.url?scp=84929552397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929552397&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-3764-2_9

DO - 10.1007/978-1-4614-3764-2_9

M3 - Chapter

AN - SCOPUS:84929552397

SN - 1461437636

SN - 9781461437635

SP - 103

EP - 119

BT - Neoplastic Diseases of the Blood

PB - Springer New York

ER -

Treatment of chronic lymphocytic leukemia and related disorders

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this